Navi Medical Technologies develops vascular access technologies for neonatal and paediatric care, including its Neonav® ECG Tip Location System that uses real-time intravascular ECG for catheter tip placement and migration surveillance. The Neonav® received US FDA 510(k) clearance in 2025 and an expanded US FDA indication in 2026 covering additional vascular access procedures, giving it broad indications for paediatric and neonatal central venous access. Clinical evaluations of Neonav® have commenced at two leading US children's hospitals. The company has operations in Australia and the United States and plans to begin US commercial sales in 2026. Recent funding will be used to scale manufacturing and build a US commercial team to support hospital launches. Navi positions Neonav® as a tool to enable ongoing catheter position reassessment and reduce repeat imaging in neonatal and paediatric intensive care.

Total raised

$7M

Funding rounds

2

Latest round

Equity

Latest activity

Jul 2026